Vivace Therapeutics clinically validates a new mechanism, though its rival Ikena reckons more specificity is needed to avoid toxicity.
This year’s AACR meeting promises a surprising amount of clinical data relevant to biopharma investors.
The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.
The company’s attempt to segment Braf-mutant cancers further isn’t going smoothly.
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
Data in the desmoid tumour niche look strong, but Ayala might provide a cheaper way for investors to play in gamma secretase inhibition.
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.